| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KLHDC2 |
| Uniprot No | Q9Y2U9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-406aa |
| 氨基酸序列 | MADGNEDLRADDLPGPAFESYESMELACPAERSGHVAVSDGRHMFVWGGYKSNQVRGLYDFYLPREELWIYNMETGRWKKINTEGDVPPSMSGSCAVCVDRVLYLFGGHHSRGNTNKFYMLDSRSTDRVLQWERIDCQGIPPSSKDKLGVWVYKNKLIFFGGYGYLPEDKVLGTFEFDETSFWNSSHPRGWNDHVHILDTETFTWSQPITTGKAPSPRAAHACATVGNRGFVFGGRYRDARMNDLHYLNLDTWEWNELIPQGICPVGRSWHSLTPVSSDHLFLFGGFTTDKQPLSDAWTYCISKNEWIQFNHPYTEKPRLWHTACASDEGEVIVFGGCANNLLVHHRAAHSNEILIFSVQPKSLVRLSLEAVICFKEMLANSWNCLPKHLLHSVNQRFGSNNTSGS |
| 预测分子量 | 46,0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KLHDC2重组蛋白的参考文献示例(注：部分内容为示例性概括，实际文献可能需要根据具体研究进一步核实)：
---
1. **文献名称**: "Recombinant KLHDC2 Expression and Interaction with Cullin E3 Ligase Complexes"
**作者**: Smith J, et al.
**摘要**: 本研究成功在大肠杆菌中表达并纯化了His标签的KLHDC2重组蛋白。通过体外结合实验，证实KLHDC2与Cullin3蛋白结合，形成功能性E3泛素连接酶复合体，可能参与底物蛋白的泛素化调控。
2. **文献名称**: "KLHDC2 Regulates p53 Stability via Direct Interaction in Colorectal Cancer"
**作者**: Zhang L, et al.
**摘要**: 利用哺乳动物表达系统制备KLHDC2重组蛋白，发现其通过Kelch结构域与肿瘤抑制蛋白p53结合，促进p53的泛素化降解，揭示了KLHDC2在结直肠癌进展中的潜在作用机制。
3. **文献名称**: "Structural Analysis of KLHDC2 Reveals Substrate-Binding Specificity"
**作者**: Tanaka K, et al.
**摘要**: 采用昆虫细胞表达系统获得高纯度KLHDC2重组蛋白，通过X射线晶体学解析其Kelch结构域的三维结构，阐明了其识别底物中特定基序的分子机制。
4. **文献名称**: "High-Throughput Screening Platform Using Recombinant KLHDC2 for Drug Discovery"
**作者**: Brown R, et al.
**摘要**: 开发了基于KLHDC2重组蛋白的体外高通量筛选平台，用于鉴定调控其与靶蛋白相互作用的小分子化合物，为相关疾病治疗提供潜在策略。
---
**注意**：以上文献为示例性内容，实际研究中请通过学术数据库(如PubMed、Web of Science)检索最新及具体研究成果。KLHDC2的功能可能与癌症、泛素化调控等通路相关，建议结合具体研究领域进一步筛选文献。
KLHDC2 (Kelch Domain-Containing Protein 2) is a member of the Kelch superfamily, characterized by conserved Kelch repeat domains that typically form β-propeller structures involved in protein-protein interactions. This gene encodes a protein containing six Kelch repeats, a BACK domain, and a C-terminal BTB/POZ domain, suggesting roles in scaffolding or substrate recognition within ubiquitin ligase complexes. While its precise biological functions remain under investigation, KLHDC2 is hypothesized to participate in cellular processes such as oxidative stress response, cell cycle regulation, and protein ubiquitination.
Recombinant KLHDC2 protein is produced using heterologous expression systems (e.g., E. coli, mammalian cells) to enable functional studies. Its recombinant form allows researchers to investigate structural properties, interaction partners, and enzymatic activities in vitro. Emerging evidence links KLHDC2 to human diseases, including potential associations with cancer progression and neurological disorders. For instance, altered KLHDC2 expression has been observed in glioblastoma and hepatocellular carcinoma, though its mechanistic contributions require further validation.
Current research focuses on characterizing KLHDC2's binding partners and regulatory networks. The BTB/POZ domain may facilitate dimerization, while Kelch repeats could mediate substrate recognition for E3 ubiquitin ligases. Recombinant protein tools are essential for deciphering these interactions and evaluating post-translational modifications. Additionally, KLHDC2 has been explored as a potential biomarker due to its differential expression patterns in pathological conditions. Ongoing studies aim to clarify its therapeutic relevance, including possible roles in drug resistance or as a target for small molecule inhibitors. The development of high-purity recombinant KLHDC2 remains critical for advancing these biomedical investigations.
×
